Avet Pharmaceuticals Announces Approval and Launch of Propofol Injectable Emulsion, USP

About Propofol

Propofol injectable emulsion is an intravenous general anesthetic and sedation drug indicated for the initiation and maintenance of Monitored Anesthesia Care (MAC) sedation, combined sedation and regional anesthesia, induction of general anesthesia, maintenance of general anesthesia, and intensive care unit (ICU) sedation of intubated, mechanically ventilated patients.

Please click here to access the full prescribing information.

DIPRIVAN® is a trademark of Fresenius Kabi USA, LLC.

About Avet Pharmaceuticals
Based in East Brunswick, New Jersey, Avet Pharmaceuticals is a rapid growth specialty pharmaceutical company engaged in the acquisition, licensing, development, marketing, sale and distribution of generic and legacy branded pharmaceutical products for the U.S. prescription drug market. Formed in 2006, the Company provides high quality generic medicines that help patients and practitioners achieve affordable healthcare solutions across a number of therapeutic categories, including but not limited to: cardiovascular, metabolic disease, anti-infectives and pain management.

SOURCE Avet Pharmaceuticals Inc.

Related posts

Spirit Christmas expands New Jersey holiday pop-ups with new 2025 locations including Toms River

Flight attendant age discrimination suit moves forward in New Jersey court against United Airlines

Judge tosses inmate’s civil rights suit against Gov. Murphy over confinement claims